Jamieson, Carol
Popova, Vanina
Daly, Ella
Cooper, Kimberly
Drevets, Wayne C.
Rozjabek, Heather M.
Singh, Jaskaran
Funding for this research was provided by:
Janssen Research & Development, LLC, United States
Article History
Received: 3 November 2022
Accepted: 20 March 2023
First Online: 8 May 2023
Declarations
:
: The TRANSFORM-2 study conducted in accordance with the ethical principles of the Declaration of Helsinki International Conference on Harmonization, Good Clinical Practice guidelines, and applicable regulatory requirements. All patients provided written informed consent. Study protocols and amendments were approved by independent review board or ethics committee for each study site.
: Not applicable.
: Ms. Jamieson, Dr. Popova, Ms. Cooper, Dr. Drevets, and Dr. Rozjabek are employees of Janssen Research & Development, LLC and may hold company stock and/or stock options. Both Drs. Singh and Daly worked on the clinical development program of esketamine for treatment-resistant depression during their employment by Janssen Research & Development, LLC; Dr. Singh is currently employed by Neurocrine Biosciences, San Diego, CA; Dr. Daly is currently a self-employed medical consultant.